Approaching Clinical Proteomics: Current State and Future Fields of Application in Cellular Proteomics

被引：47

作者：

Apweiler, Rolf ^{[2
]}

Aslanidis, Charalampos ^{[1
]}

Deufel, Thomas ^{[3
,4
]}

Gerstner, Andreas ^{[5
]}

Hansen, Jens ^{[1
]}

Hochstrasser, Dennis ^{[6
]}

Kellner, Roland ^{[7
]}

Kubicek, Markus ^{[8
]}

Lottspeich, Friedrich ^{[9
]}

Maser, Edmund ^{[10
]}

Mewes, Hans-Werner ^{[11
]}

Meyer, Helmut E. ^{[12
]}

Muellner, Stefan ^{[13
]}

Mutter, Wolfgang ^{[14
]}

Neumaier, Michael ^{[15
]}

Nollau, Peter ^{[17
]}

Nothwang, Hans G. ^{[16
]}

Ponten, Fredrik ^{[18
]}

Radbruch, Andreas ^{[19
]}

Reinert, Knut ^{[20
]}

Rothe, Gregor ^{[21
]}

Stockinger, Hannes ^{[22
]}

Tarnok, Attila ^{[23
]}

Taussig, Mike J. ^{[24
]}

Thiel, Andreas ^{[19
]}

Thiery, Joachim ^{[25
]}

Ueffing, Marius ^{[26
]}

Valet, Guenther ^{[9
]}

Vandekerckhove, Joel ^{[27
]}

Wagener, Christoph ^{[17
]}

Wagner, Oswald ^{[28
]}

Schmitz, Gerd ^{[1
]}

机构：

[1] Univ Regensburg, Inst Clin Chem & Lab Med, D-93053 Regensburg, Germany

[2] European Bioinformat Inst, Hinxton, England

[3] Univ Jena, Inst Clin Chem, Jena, Germany

[4] Univ Jena, Diagnost Lab, Jena, Germany

[5] Univ Bonn, Dept Otorhinolaryngol Surg, D-5300 Bonn, Germany

[6] Univ Geneva, Dept Pathol Clin Chem, Geneva, Switzerland

[7] Merck, Darmstadt, Germany

[8] Med Univ Vienna, Ctr Bioinformat & Clin Prote, Vienna, Austria

[9] Max Planck Inst Biochem, D-82152 Martinsried, Germany

[10] Univ Kiel, Inst Pharmacol & Toxicol, Kiel, Germany

[11] GSF, Inst Bioinformat, Neuherberg, Germany

[12] Ruhr Univ Bochum, Med Prote Ctr, Bochum, Germany

[13] Protagen, Dortmund, Germany

[14] PROFOS, Regensburg, Germany

[15] Univ Hosp Mannheim, Inst Clin Chem, Mannheim, Germany

[16] Tech Univ Kaiserslautern, Dept Anim Physiol, Kaiserslautern, Germany

[17] Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem, Hamburg, Germany

[18] Uppsala Univ, Inst Genet & Pathol, Uppsala, Sweden

[19] German Rheumatism Res Ctr, Berlin, Germany

[20] Univ Berlin, Dept Math & Comp Sci, Berlin, Germany

[21] Lab Ctr Bremen, Bremen, Germany

[22] Univ Vienna, Dept Mol Immunol, Vienna, Austria

[23] Univ Leipzig, Dept Pediat Cardiol, Leipzig, Germany

[24] Babraham Inst, Technol Res Grp, Cambridge, England

[25] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany

[26] GSF, Inst Human Genet, Neuherberg, Germany

[27] Univ Ghent, Dept Med Prot Res, B-9000 Ghent, Belgium

[28] Univ Vienna, Inst Med & Chem Lab Diagnost, Vienna, Austria

来源：

CYTOMETRY PART A | 2009年 / 75A卷 / 10期

关键词：

clinical proteomics; cellular proteomics; cytomics; cytoproteomics; proteome; SLIDE-BASED CYTOMETRY; 2-DIMENSIONAL GEL-ELECTROPHORESIS; ANTIBODY-BASED PROTEOMICS; TANDEM MASS-SPECTROMETRY; LASER-SCANNING CYTOMETRY; LIPID RAFT PROTEINS; RED-BLOOD-CELLS; FLOW-CYTOMETRY; PLATELET-FUNCTION; MEMBRANE MICRODOMAINS;

D O I：

10.1002/cyto.a.20779

中图分类号：

Q5 [生物化学];

学科分类号：

070307 [化学生物学];

摘要：

Recent developments in proteomics technology offer new opportunities for clinical applications in hospital or specialized laboratories including the identification of novel biomarkers, monitoring of disease, detecting adverse effects of drugs, and environmental hazards. Advanced spectrometry technologies and the development of new protein array formats have brought these analyses to a standard, which now has the potential to be used in clinical diagnostics. Besides standardization of methodologies and distribution of proteomic data into public databases, the nature of the human body fluid proteome with its high dynamic range in protein concentrations, its quantitation problems, and its extreme complexity present enormous challenges. Molecular cell biology (cytomics) with its link to proteomics is a new fast moving scientific field, which addresses functional cell analysis and bioinformatic approaches to search for novel cellular proteomic biomarkers or their release products into body fluids that provide better insight into the enormous biocomplexity of disease processes and are suitable for patient stratification, therapeutic monitoring, and prediction of prognosis. Experience from studies of in vitro diagnostics and especially in clinical chemistry showed that the majority of errors occurs in the preanalytical phase and the setup of the diagnostic strategy. This is also true for clinical proteomics where similar preanalytical variables such as inter- and intra-assay variability due to biological variations or proteolytical activities in the sample will most likely also influence the results of proteomics studies. However, before complex proteomic analysis can be introduced at a broader level into the clinic, standardization of the preanalytical phase including patient preparation, sample collection, sample preparation, sample storage, measurement, and data analysis is another issue which has to be improved. In this report, we discuss the recent advances and applications that fulfill the criteria for clinical proteomics with the focus on cellular proteomics (cytoproteomics) as related to preanalytical and analytical standardization and to quality control measures required for effective implementation of these technologies and analytes into routine laboratory testing to generate novel actionable health information. It will then be crucial to design and carry out clinical studies that can eventually identify novel clinical diagnostic strategies based on these techniques and validate their impact on clinical decision making. (C) 2009 International Society for Advancement of Cytometry

引用

页码：816 / 832

页数：17

共 133 条

[1]

Proteomics opens doors to the mechanisms of developmentally regulated secretion [J].